OR WAIT 15 SECS
© 2020 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2020 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
November 02, 2020
The agency is balancing a variety of important issues including the review of COVID-19 vaccines.
October 02, 2020
Regulatory bodies are adapting to new ways of working to cope with the impact of COVID-19.
September 02, 2020
The 2020–2025 EMRN strategy will be regularly reviewed over the coming five years to accommodate science and technology advances.
August 02, 2020
EU regulators are requesting more effective action be taken to tackle serious impurities in APIs and finished products.
July 02, 2020
EMA is facing a dilemma in trying to restore activities back to normal after relocating and the COVID-19 pandemic.
June 02, 2020
The EU’s pharmaceutical strategy has the potential to shake up the policies and regulations of the region’s medicines sector.
May 02, 2020
EMA’s strategy for regulatory science has divided opinion amongst various industry bodies.
April 02, 2020
Regulatory emergency planning has been put to the test with the COVID-19 pandemic.
March 02, 2020
EU regulators have accelerated their efforts to use the mass of data emerging from the lifecycles of drugs as an effective basis for both the development and control of medicines.
February 02, 2020
The UK and Europe are entering a transitional period, which will involve negotiations across the board, including those on the pharma regulatory landscape.